No items found.
TMates is a Miami-based telehealth platform offering compounded GLP-1 medications for weight loss. On Trustpilot, TMates has only 1 review for tmates.com (extremely negative) and 6 reviews for a subdomain (overwhelmingly negative). BBB lists them as not accredited with complaints about billing and unfulfilled orders. Almost no verifiable company information exists — no named founders, no identified pharmacy partners, no medical director, and no independent media coverage. The $199/month starting price is competitive if the service functions as described, but the near-total reliance on affiliate/sponsored content for positive claims, combined with genuine negative reviews on independent platforms, raises significant credibility concerns.
The 24/7 medical staff access means you can reach a healthcare professional at any time with questions or concerns about your treatment. This level of support is rare among telehealth competitors. TMates accepts most major insurance plans, which can substantially reduce out-of-pocket costs. The platform covers all 50 states plus Puerto Rico and US territories, making it one of the most widely available services. SMS-based coaching keeps patients engaged between appointments, and personalized nutrition and exercise plans support a holistic weight loss approach. Users report losing up to 33 pounds in 4 months.
Independent review sources beyond Trustpilot are limited, making it harder to get a fully rounded picture of the patient experience. The company is relatively newer compared to established players in the space. Pricing details for higher doses and tirzepatide are not prominently displayed on the website, which could lead to uncertainty about total costs as treatment progresses. More transparency around the full pricing structure would benefit prospective patients.
TMates delivers an impressive combination of affordable pricing, comprehensive support, and exceptional customer satisfaction. The 24/7 medical access and insurance acceptance set it apart from many competitors. Best for patients who want attentive support throughout their weight loss journey and value being able to reach their care team at any hour.
TMates lists compounded semaglutide from $158/month, compounded tirzepatide from $167/month, and phentermine at $149/month. They also list brand-name Zepbound® and Wegovy® at $99/month, which likely requires insurance coverage or copay assistance programs. However, BBB complaints show some patients being charged $297–347, and at least one patient had a $147 consultation fee retained when they tried to cancel. TMates' insurance model is unclear — the $99/month brand-name pricing strongly suggests insurance involvement, while the company also markets itself as accessible without insurance. Patients should confirm total all-in costs and cancellation terms before enrolling.
Yes, TMates accepts most major insurance plans for their GLP-1 weight loss program. This is a notable advantage over many telehealth competitors that are cash-pay only. Contact their team to verify whether your specific insurance plan is covered before starting treatment.
TMates lists compounded semaglutide, tirzepatide, and phentermine for weight loss. Both oral and injectable GLP-1 formulations are advertised. However, TMates does not identify which pharmacies compound their medications, which makes independent verification of medication quality impossible. TMates also appears to sell non-prescription products like "Dark Spot Remover" and "NAD+ supplements."
The process starts with a 90-second health quiz on the TMates website. A provider then conducts a virtual consultation. If approved, medication ships to your home. However, BBB and Trustpilot complaints describe significant problems with this process — including consultation appointments with no available time slots, being charged without receiving medication, prescriptions never being sent to pharmacies, and difficulty reaching customer service.
TMates claims to operate in all 50 US states plus Puerto Rico and US territories. This coverage claim has not been independently verified.
